Jazz Pharmaceuticals (JAZZ) Proxy filing summary
Event summary combining transcript, slides, and related documents.
Proxy filing summary
8 Jun, 2026Executive summary
Annual General Meeting scheduled for July 23, 2026, in Dublin, Ireland, with voting available online, by mail, or in person.
Shareholders as of May 28, 2026, are eligible to vote on key proposals, including director elections and auditor appointment.
Voting matters and shareholder proposals
Election of three directors to serve until the 2029 Annual General Meeting: Bruce C. Cozadd, Heather Ann McSharry, and Rick E Winningham.
Advisory vote to approve KPMG as independent auditors for fiscal year ending December 31, 2026, and authorize the Board to set their remuneration.
Advisory vote on executive compensation as disclosed in the proxy statement.
Proposal to grant the Board authority to allot and issue ordinary shares under Irish law.
Proposal to allow the Board to issue shares for cash without pre-emption rights.
Proposal to approve adjournment of the meeting if more time is needed to solicit proxies for share issuance proposals.
Board of directors and corporate governance
Board recommends voting in favor of all proposals, including director elections and share issuance authorities.
Latest events from Jazz Pharmaceuticals
- Proxy covers director elections, auditor ratification, compensation, and share issuance authority renewal.JAZZ
Proxy filing8 Jun 2026 - Zanidatamab's clinical success drives rapid expansion into new oncology markets and indications.JAZZ
Jefferies Global Healthcare Conference 20263 Jun 2026 - Zanidatamab nears approval in frontline GEA, with robust data and expanding indications.JAZZ
7th Annual Oncology Innovation Summit: Insights for ASCO & EHA31 May 2026 - Board recommends all proxy proposals, citing strong performance, governance, and growth strategy.JAZZ
Proxy filing29 May 2026 - Zanidatamab delivers unprecedented survival in HER2 cancers, with broad expansion and launch readiness.JAZZ
RBC Capital Markets Global Healthcare Conference 202619 May 2026 - Q1 2026 revenue up 19% to $1.1B, with strong growth in key products and pipeline advances.JAZZ
Q1 20265 May 2026 - Sharpened rare disease focus and advancing pipeline drive continued growth and momentum.JAZZ
25th Annual Needham Virtual Healthcare Conference22 Apr 2026 - Record growth in 2025, pipeline advances, and strategic investments drive future expansion.JAZZ
Barclays 28th Annual Global Healthcare Conference12 Mar 2026 - Record growth, pipeline advances, and rare disease focus drive strong 2026 outlook.JAZZ
TD Cowen 46th Annual Health Care Conference3 Mar 2026